Literature DB >> 19280364

Four successful pregnancies in a patient with mucopolysaccharidosis type I treated by allogeneic bone marrow transplantation.

G Remérand1, E Merlin, R Froissart, F Brugnon, J Kanold, L Janny, F Deméocq.   

Abstract

To date, little is known about the fertility of women suffering from mucopolysaccharidosis type I (MPS I). We report on a female patient with MPS I treated by allogeneic bone marrow transplantation (BMT) at the age of 4 years (after a conditioning regimen containing busulfan 16 mg/kg and cyclophosphamide 100 mg/kg) who had four successful pregnancies without any reproductive assistance. Clinical and biological examinations of the children were normal. On the basis of this case, we discuss the fertility counselling of female MPS I patients at the time of BMT.

Entities:  

Mesh:

Year:  2009        PMID: 19280364     DOI: 10.1007/s10545-009-1095-y

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  15 in total

1.  A strategy for fertility services for survivors of childhood cancer.

Authors: 
Journal:  Hum Fertil (Camb)       Date:  2003-05       Impact factor: 2.767

Review 2.  Ovarian tissue and oocyte cryopreservation.

Authors: 
Journal:  Fertil Steril       Date:  2006-11       Impact factor: 7.329

3.  Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg).

Authors:  A P Grigg; R McLachlan; J Zaja; J Szer
Journal:  Bone Marrow Transplant       Date:  2000-11       Impact factor: 5.483

4.  Molecular analysis of 30 mucopolysaccharidosis type I patients: evaluation of the mutational spectrum in Italian population and identification of 13 novel mutations.

Authors:  N Venturi; A Rovelli; R Parini; F Menni; F Brambillasca; F Bertagnolio; G Uziel; R Gatti; M Filocamo; M A Donati; A Biondi; S Goldwurm
Journal:  Hum Mutat       Date:  2002-09       Impact factor: 4.878

5.  Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue.

Authors:  Claus Yding Andersen; Mikkel Rosendahl; Anne Grete Byskov; Anne Loft; Christian Ottosen; Margit Dueholm; Kirsten L T Schmidt; Anders Nyboe Andersen; Erik Ernst
Journal:  Hum Reprod       Date:  2008-07-03       Impact factor: 6.918

6.  Follicular growth and estradiol follow-up after subcutaneous xenografting of fresh and cryopreserved human ovarian tissue.

Authors:  Benoit Schubert; Michel Canis; Claude Darcha; Christine Artonne; Johan Smitz; Genevieve Grizard
Journal:  Fertil Steril       Date:  2007-08-20       Impact factor: 7.329

7.  Cord-blood transplants from unrelated donors in patients with Hurler's syndrome.

Authors:  Susan L Staba; Maria L Escolar; Michele Poe; Young Kim; Paul L Martin; Paul Szabolcs; June Allison-Thacker; Susan Wood; David A Wenger; Pablo Rubinstein; John J Hopwood; William Krivit; Joanne Kurtzberg
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

8.  Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation.

Authors:  J E Sanders; J Hawley; W Levy; T Gooley; C D Buckner; H J Deeg; K Doney; R Storb; K Sullivan; R Witherspoon; F R Appelbaum
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

Review 9.  Cryopreservation/transplantation of ovarian tissue and in vitro maturation of follicles and oocytes: challenges for fertility preservation.

Authors:  Alex C Varghese; Stefan S du Plessis; Tommaso Falcone; Ashok Agarwal
Journal:  Reprod Biol Endocrinol       Date:  2008-10-02       Impact factor: 5.211

10.  Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure.

Authors:  J J Boelens; R F Wynn; A O'Meara; P Veys; Y Bertrand; G Souillet; J E Wraith; A Fischer; M Cavazzana-Calvo; K W Sykora; P Sedlacek; A Rovelli; C S P M Uiterwaal; N Wulffraat
Journal:  Bone Marrow Transplant       Date:  2007-05-28       Impact factor: 5.483

View more
  9 in total

1.  Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function.

Authors:  Zeev Blumenfeld
Journal:  Oncologist       Date:  2012-02-02

2.  Repeated spontaneous pregnancies and successful deliveries after repeated autologous stem cell transplantation and GnRH-agonist treatment.

Authors:  Zeev Blumenfeld; Tsila Zuckerman
Journal:  Oncologist       Date:  2010-01-12

3.  Morphologic description of male reproductive accessory glands in a mouse model of mucopolysaccharidosis type I (MPS I).

Authors:  Cinthia Castro do Nascimento; Odair Aguiar Junior; Vânia D'Almeida
Journal:  J Mol Histol       Date:  2020-03-11       Impact factor: 2.611

4.  Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.

Authors:  Zeev Blumenfeld; Hilli Zur; Eldad J Dann
Journal:  Oncologist       Date:  2015-10-13

5.  Analysis of male reproductive parameters in a murine model of mucopolysaccharidosis type I (MPS I).

Authors:  Cinthia Castro do Nascimento; Odair Aguiar Junior; Vânia D'Almeida
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

6.  Fertility Preservation in Leukemia.

Authors:  Zeev Blumenfeld
Journal:  Oncologist       Date:  2018-02-07

Review 7.  Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy.

Authors:  Zeev Blumenfeld
Journal:  Clin Med Insights Reprod Health       Date:  2019-08-21

8.  Pregnancy in patients with mucopolysaccharidosis: a case series.

Authors:  Fiona J Stewart; Andrew Bentley; Barbara K Burton; Nathalie Guffon; Susan L Hale; Paul R Harmatz; Susanne G Kircher; Pavan K Kochhar; John J Mitchell; Ursula Plöckinger; Sue Graham; Stephen Sande; Zlatko Sisic; Tracey A Johnston
Journal:  Mol Genet Metab Rep       Date:  2016-08-29

9.  Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I).

Authors:  Ana Barbosa Mendes; Cinthia Castro do Nascimento; Vânia D'Almeida
Journal:  PLoS One       Date:  2019-12-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.